Ionis Pharmaceuticals Inc (IONS)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$44.12

+1.42 (+3.33%)

Market Cap: $7.26B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

77%(30/39)

Avg Surprise

+66.29%

Streak

14 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.92

Range$-1.06 - $-0.65

8 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.84-8.7%

60d ago$-0.81-13.7%

30d ago$-0.920.0%

7d ago$-0.920.0%

Current$-0.92

Revenue Consensus

$186M

Range$156M - $225M

18 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.13

Range$-1.13 - $0.45

10 analysts

Revenue Consensus

$347M

Range$211M - $605M

23 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.13	$-1.13 - $0.45	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$-0.92	$-1.06 - $-0.65	-	-	8	1 5 30d	-
Jun 30, 2026Jun 26 Reported Jul 29, 2026Reported Jul 29	$-0.70	$-1.09	$-1.24 - $-0.85	+35.78%	Beat	6	4 2 30d	-182.4%
Mar 31, 2026Mar 26 Reported Apr 29, 2026Reported Apr 29	$-0.30	N/A	-	+61.04%	Beat	8	0 2 30d	+67.4%
Dec 31, 2025Dec 25 Reported Feb 25, 2026Reported Feb 25	$-1.15	$-1.33	$-1.42 - $-0.99	+13.68%	Beat	7	0 1 30d	-166.8%
Sep 30, 2025Sep 25 Reported Oct 29, 2025Reported Oct 29	$-0.61	$-1.05	$-1.33 - $-0.88	+41.90%	Beat	8	1 0 30d	+35.8%
Jun 30, 2025Jun 25 Reported Jul 30, 2025Reported Jul 30	$0.85	$0.16	$-0.45 - $0.60	+431.25%	Beat	7	2 0 30d	+454.2%
Mar 31, 2025Mar 25 Reported Apr 30, 2025Reported Apr 30	$-0.92	$-1.03	$-1.35 - $-0.82	+10.68%	Beat	6	2 0 30d	-19.5%
Dec 31, 2024Dec 24 Reported Feb 19, 2025Reported Feb 19	$-0.43	$-0.84	$-1.04 - $-0.70	+49.03%	Beat	9	1 0 30d	-617.3%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$-0.95	$-1.16	$-1.32 - $-0.94	+18.10%	Beat	17	3 0 30d	-11.8%
Jun 30, 2024Jun 24 Reported Aug 1, 2024Reported Aug 1	$-0.24	N/A	-	+68.42%	Beat	18	7 0 30d	+41.5%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$-0.77	$-0.83	$-1.38 - $-0.62	+7.23%	Beat	16	2 2 30d	-13.2%
Dec 31, 2023Dec 23 Reported Feb 21, 2024Reported Feb 21	$-0.06	N/A	-	+92.77%	Beat	17	2 0 30d	+95.6%
Sep 30, 2023Sep 23 Reported Nov 2, 2023Reported Nov 2	$-0.85	$-0.89	$-1.25 - $-0.74	+4.49%	Beat	16	1 3 30d	-431.3%
Jun 30, 2023Jun 23 Reported Aug 9, 2023Reported Aug 9	$-0.41	$-0.70	-	+41.43%	Beat	16	3 0 30d	+26.8%
Mar 31, 2023Mar 23 Reported May 3, 2023Reported May 3	$-0.68	$-0.76	$-1.43 - $-0.61	+10.53%	Beat	16	2 0 30d	-151.9%
Dec 31, 2022Dec 22 Reported Feb 22, 2023Reported Feb 22	$-1.36	$-0.92	$-1.62 - $0.11	-47.83%	Miss	14	1 1 30d	-196.5%
Sep 30, 2022Sep 22 Reported Nov 9, 2022Reported Nov 9	$-0.16	N/A	-	+69.81%	Beat	16	1 0 30d	+52.9%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-0.56	$-0.47	$-0.85 - $-0.32	-19.15%	Miss	17	1 2 30d	-115.4%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-0.27	$-0.52	-	+48.08%	Beat	17	No revisions (30d)	+15.6%
Dec 31, 2021Dec 21 Reported Feb 24, 2022Reported Feb 24	$1.41	$0.28	$-0.29 - $1.68	+403.57%	Beat	15	2 0 30d	+220.5%
Sep 30, 2021Sep 21 Reported Nov 3, 2021Reported Nov 3	$-0.34	$-0.32	$-0.81 - $-0.14	-6.25%	Miss	15	2 0 30d	-54.5%
Jun 30, 2021Jun 21 Reported Aug 4, 2021Reported Aug 4	$-0.26	$-0.32	-	+18.75%	Beat	16	4 0 30d	-13.0%
Mar 31, 2021Mar 21 Reported May 5, 2021Reported May 5	$-0.32	$-0.25	$-1.01 - $0.53	-28.00%	Miss	15	1 0 30d	+8.6%
Dec 31, 2020Dec 20 Reported Feb 24, 2021Reported Feb 24	$0.44	$0.28	$0.05 - $0.50	+57.14%	Beat	16	4 0 30d	-68.8%
Sep 30, 2020Sep 20 Reported Nov 4, 2020Reported Nov 4	$-0.22	$-0.16	$-0.32 - $0.43	-37.50%	Miss	17	No revisions (30d)	-222.2%
Jun 30, 2020Jun 20 Reported Aug 5, 2020Reported Aug 5	$-0.23	$-0.28	$-0.48 - $-0.07	+17.86%	Beat	18	No revisions (30d)	-2200.0%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$-0.35	$-0.11	$-0.40 - $0.18	-218.18%	Miss	18	2 0 30d	-156.5%
Dec 31, 2019Dec 19 Reported Feb 26, 2020Reported Feb 26	$1.41	$0.93	$0.19 - $1.32	+51.61%	Beat	18	No revisions (30d)	+642.1%
Sep 30, 2019Sep 19 Reported Nov 6, 2019Reported Nov 6	$0.18	$-0.32	$-0.59 - $-0.17	+156.25%	Beat	14	2 0 30d	+700.0%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-0.01	N/A	-	+95.00%	Beat	15	1 0 30d	+96.6%
Mar 31, 2019Mar 19 Reported May 9, 2019Reported May 9	$0.62	$0.78	$-0.39 - $1.18	-20.51%	Miss	14	No revisions (30d)	+6300.0%
Dec 31, 2018Dec 18 Reported Feb 27, 2019Reported Feb 27	$0.19	$-0.05	$-0.27 - $0.23	+480.00%	Beat	13	No revisions (30d)	+850.0%
Sep 30, 2018Sep 18 Reported Nov 6, 2018Reported Nov 6	$-0.03	N/A	-	+82.35%	Beat	11	1 0 30d	-782.4%
Jun 30, 2018Jun 18 Reported Aug 7, 2018Reported Aug 7	$-0.29	$-0.19	$-0.45 - $0.50	-52.63%	Miss	11	No revisions (30d)	-222.2%
Mar 31, 2018Mar 18 Reported May 4, 2018Reported May 4	$-0.01	N/A	-	+93.33%	Beat	10	2 0 30d	-133.3%
Dec 31, 2017Dec 17 Reported Feb 27, 2018Reported Feb 27	$0.02	$0.01	$-0.50 - $0.51	+100.00%	Beat	12	3 0 30d	-91.7%
Sep 30, 2017Sep 17 Reported Nov 7, 2017Reported Nov 7	$-0.00	N/A	-	+95.75%	Beat	12	2 0 30d	-
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-0.09	$-0.06	$-0.57 - $0.19	-50.00%	Miss	9	5 0 30d	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$0.03	N/A	-	+109.68%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Feb 28, 2017Reported Feb 28	$0.24	$-0.12	-	+300.00%	Beat	-	-	-

Dividends

Dividend Metrics

Forward Yield0.00%

Forward Annual Dividend$0.00

No dividend payments in the selected period.

Key Metrics

Valuation
P/E Ratio	-16.00	EV/EBITDA	N/A
Price/FCF	-13.01x	FCF Yield	-7.68%
Profitability
Profit Margin	-64.70%	Operating Margin	-38.20%
ROE	-105.50%	ROIC	-30.11%
Financial Health
Debt/Equity	3.60x	Interest Coverage	-6.81x
Current Ratio	7.89x	Quick Ratio	7.73x
Trading Statistics
Beta	0.38	Avg Volume	3.85M
52-Week High	$86.74	52-Week Low	$42.36

Technical Indicators Dashboard

Moving Averages

SMA 10$43.66

SMA 20$44.20

SMA 50$51.96

SMA 200$68.78

EMA 10$43.86

EMA 20$45.38

EMA 50$50.72

EMA 200$61.58

MACD

Line: -2.41Signal: -2.84Hist: 0.43

ADX

ADX: 41.0+DI: 18.1-DI: 30.2

Aroon & PSAR

Aroon Up4.0

Aroon Down96.0

PSAR$45.44

Bollinger Bands

Upper Band$46.10

Lower Band$42.31

%B Position857%(Upper)

Band Width0.48

RSI (14-Day)

Neutral

40.9

Momentum Oscillators

Stoch %K18.4

Stoch %D19.8

Williams %R-58.1

ROC (10d)0.3%

Momentum0.12

CCI (20d)-22.0

MFI (14d)50.6

Volatility Measures

ATR (14d)$1.86(4.2%)

StdDev (20d)0.95

Hist Vol40.2%(High)

Volume Flow

VWAP$44.08

OBV22.7M

AD Line5.3M

CMF (20d)-0.129

Volume Metrics

Avg Vol (20d)3.6M

Vol Ratio0.7x

VWMA (20d)$44.35

Pivot Points

R3$44.81

R2$44.14

R1$43.42

Pivot Point$42.75

S1$42.03

S2$41.36

S3$40.64

Advanced Oscillators

TSI-31.06

Ultimate Osc44.9

KST-172.31

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$267.95M	$246.09M	$203.33M	$156.72M	$452.05M	$131.61M	$226.58M	$133.81M	$225.25M	$119.50M	$324.50M	$144.21M
Cost of Revenue	$2.74M	$2.98M	$7.96M	$2.34M	$4.15M	$1.46M	$3.83M	$1.07M	$4.16M	$2.15M	$3.06M	$2.19M
Gross Profit	$265.21M	$243.11M	$195.37M	$154.38M	$447.90M	$130.15M	$222.75M	$132.74M	$221.09M	$117.35M	$321.44M	$142.02M

Operating Expenses	$367.50M	$360.53M	$409.83M	$314.56M	$308.08M	$277.01M	$333.57M	$281.40M	$287.18M	$266.86M	$327.56M	$285.28M
R&D	$217.11M	$210.17M	$279.65M	$217.75M	$217.46M	$200.76M	$245.49M	$219.76M	$222.06M	$214.22M	$256.56M	$215.33M
SG&A	$150.40M	$150.36M	$130.19M	$96.81M	$90.62M	$76.25M	$88.08M	$61.64M	$65.11M	$52.64M	$71.01M	$69.95M
Operating Income	$-102,293,000	$-117,424,000	$-214,458,000	$-160,182,000	$139.82M	$-146,860,000	$-110,821,000	$-148,656,000	$-66,091,000	$-149,513,000	$-6,122,000	$-143,265,000

Interest Income	$10.05M	$48.07M	$25.52M	$53.59M	$6.38M	$22.50M	$26.34M	$27.11M	$22.07M	$28.62M	$25.53M	$21.99M
Interest Expense	$22.12M	$22.50M	$22.69M	$22.16M	$22.76M	$22.93M	$22.86M	$22.69M	$22.79M	$22.11M	$22.41M	$21.98M
Income Before Tax	$-113,382,000	$-92,310,000	$-227,917,000	$-128,393,000	$123.53M	$-146,822,000	$-107,038,000	$-144,101,000	$-66,201,000	$-142,728,000	$-2,766,000	$-140,808,000
Income Tax Expense	$1.26M	$218,000	$1.48M	$213,000	$-20,000	$116,000	$-2,689,000	$-3,621,000	$64,000	$75,000	$6.50M	$6.60M

Net Income	$-114,646,000	$-92,528,000	$-229,394,000	$-128,606,000	$123.55M	$-146,938,000	$-104,349,000	$-140,480,000	$-66,265,000	$-142,803,000	$-9,263,000	$-147,410,000

EBITDA	$-95,210,000	$-114,274,000	$-227,109,000	$-158,750,000	$141.15M	$-146,464,000	$-113,028,000	$-150,483,000	$-68,117,000	$-151,175,000	$-7,100,000	$-141,442,000
EBIT	$-101,306,000	$-117,880,000	$-230,746,000	$-159,819,000	$139.92M	$-146,395,000	$-110,519,000	$-148,514,000	$-65,481,000	$-149,236,000	$-5,887,000	$-140,818,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about IONS

News

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Ionis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended TRYNGOLZA® (olezarsen) for approval in the EU for severe...

BioSpace•Oct 16, 2026 9:30 AM ET10/16/26•Bullish

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS)

Analysts have issued bullish ratings for Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS). Truist Financial maintained a Buy rating for Boston Scientific with a $51.00 price target...

The Globe and Mail•Oct 15, 2026 10:09 PM ET10/15/26•Bullish

Lobbying Update: $150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed

IONIS PHARMACEUTICALS INC. (IONS) disclosed $150,000 in lobbying expenditures for Q3 2026, focusing on issues like the Inflation Reduction Act and drug pricing. The report also details recent insider trading activity...

Quiver Quantitative•Oct 15, 2026 5:40 PM ET10/15/26•Somewhat-Bearish

Ionis Pharmaceuticals Shares Rise After UBS Upgrade

Ionis Pharmaceuticals (IONS) stock rose 3.2% on Thursday following an upgrade from UBS, which changed its rating on the company to "buy." The article is very brief and indicates that further details are available...

Yahoo Finance•Oct 15, 2026 8:14 AM ET10/15/26•Bullish

Ionis Pharmaceuticals stock hits 52-week low at 42.63 USD By Investing.com

Ionis Pharmaceuticals (IONS) stock has fallen to a 52-week low of $42.63, reflecting a 44.8% year-to-date decline and a market capitalization of $7.09 billion. Despite this downturn...

Investing.com India•Oct 13, 2026 12:20 PM ET10/13/26•Bearish

IONS Valuation and Fair Value

P/E: -16.0x
Forward P/E: 90.9x
P/FCF: -13.0x
PEG: 25.7x
P/B: 16.6x

See GNG's fair value

IONS Profitability: Margins, ROIC and FCF

Gross margin: 98.2%
Operating margin: -38.2%
Net margin: -64.7%
ROIC: -30.1%
ROE: -105.5%
FCF margin: -64.2%
FCF yield: -7.7%

IONS Competitors

Company	Ticker
Spyre Therapeutics Inc.	SYRE
PACS Group, Inc.	PACS
HealthEquity Inc	HQY
Merus BV	MRUS
AptarGroup Inc	ATR
Praxis Precision Medicines Inc	PRAX
Abivax SA American Depositary Shares	ABVX
Amneal Pharmaceuticals, Inc. Class A Common Stock	AMRX

Sector: Healthcare

IONS Analyst Ratings

Consensus: Buy
Analysts: 24
Strong Buy: 9
Buy: 10
Hold: 5
Sell: 0
Strong Sell: 0

IONS Bull Case vs Bear Case

Bull case

IONS beat EPS estimates in 100.0% of its last 8 reported quarters.
79.2% of IONS's analyst ratings are Buy or Strong Buy.

Bear case

IONS has a -64.7% net profit margin.
IONS's quarterly revenue changed -40.7% year over year.
IONS has a debt-to-equity ratio of 3.6x.

IONS Earnings: Beat Rate and Next Report

Beat rate: 8 of 8 quarters (100.0%)
Average surprise: 82.7%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.92
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 5 down

IONS Dividend

Forward yield: 0.0%

Frequently Asked Questions About IONS

Does IONS pay dividends?

Ionis Pharmaceuticals Inc (IONS) has a dividend payment track record. See the IONS dividend history page for its current payment status, TTM yield, and recorded payments.

What is IONS's market cap?

Ionis Pharmaceuticals Inc (IONS) has a market capitalization of $7.26B with a current stock price of $44.12.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In